Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan

Journal of Veterinary Medical Science

Volumn 76, Issue 5, 2014, Pages 661-666

  Takahashi, Masashi ^a   Tomiyasu, Hirotaka ^a   Hotta, Eri ^a   Asada, Hajime ^a   Fukushima, Kenjiro ^a   Kanemoto, Hideyuki ^a   Fujino, Yasuhito ^a   Ohno, Koichi ^a   Uchida, Kazuyuki ^a   Nakayama, Hiroyuki ^a   Tsujimoto, Hajime ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Canine; Histiocytic sarcoma; Prognostic factor; Retrospective study

Indexed keywords

ANIMAL; BLOOD ANALYSIS; BLOOD CELL COUNT; DOG; DOG DISEASES; HISTIOCYTIC SARCOMA; JAPAN; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; SPECIES DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; VETERINARY;

ANIMALS; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; DOG DISEASES; DOGS; HISTIOCYTIC SARCOMA; JAPAN; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84901761300     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.13-0414     Document Type: Article

References (15)

1. Affolter, V. K. and Moore, P. F. 2002. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet. Pathol. 39: 74-83. [CrossRef] [Medline]
2. Carr, A. P., Panciera, D. L. and Kidd, L. 2002. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 dogs. J. Vet. Intern. Med. 16: 504-509. [CrossRef] [Medline]
3. Constantino-Casas, F., Mayhew, D., Hoather, T. M. and Dobson, J. M. 2011. The clinical presentation and histopathologic-immunohistochemical classification of histiocytic sarcomas in the flat coated retriever. Vet. Pathol. 48: 764-771. [CrossRef] [Medline]
4. Fidel, J., Schiller, I., Hauser, B., Jausi, Y., Rohrer-Bley, C., Roos, M. and Kaser-Hotz, B. 2006. Histiocytic sarcomas in flat-coated retrievers: a summary of 37 cases (November 1998-March 2005). Vet. Comp. Oncol. 4: 63-74. [CrossRef] [Medline]
5. Ide, T., Uchida, K., Kagawa, Y., Suzuki, K. and Nakayama, H. 2011. Pathological and immunohistochemical features of subdural histiocytic sarcomas in 15 dogs. J. Vet. Diagn. Invest. 23: 127-132. [CrossRef] [Medline]
6. Moore, P. F., Affolter, V. K. and Vernau, W. 2006. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet. Pathol. 43: 632-645. [CrossRef] [Medline]
7. Nguyen, S. M., Thamm, D. H., Vail, D. M. and London, C. A. 2013. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet. Comp. Oncol. [CrossRef]. [Medline]
8. Padgett, G. A., Madewell, B. R., Keller, E. T., Jodar, L. and Packard, M. 1995. Inheritance of histiocytosis in Bernese mountain dogs. J. Small Anim. Pract. 36: 93-98. [CrossRef] [Medline]
9. Poirier, V. J., Hershey, A. E., Burgess, K. E., Phillips, B., Turek, M. M., Forrest, L. J., Beaver, L. and Vail, D. M. 2004. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J. Vet. Intern. Med. 18: 219-222. [CrossRef] [Medline]
10. Rassnick, K. M., Moore, A. S., Russell, D. S., Northrup, N. C., Kristal, O., Bailey, D. B., Flory, A. B., Kiselow, M. A. and Intile, J. L. 2010. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J. Vet. Intern. Med. 24: 1528-1531. [CrossRef] [Medline]
11. Shaiken, S. C., Evans, S. M. and Goldschmidt, M. H. 1991. Radiographic findings in canine malignant histiocytosis. Vet. Radiol. 32: 237-242. [CrossRef]
12. Skorupski, K. A., Clifford, C. A., Paoloni, M. C., Lara-Garcia, A., Barber, L., Kent, M. S., LeBlanc, A. K., Sabhlok, A., Mauldin, E. A., Shofer, F. S., Couto, C. G. and Sørenmo, K. U. 2007. CCNU for the treatment of dogs with histiocytic sarcoma. J. Vet. Intern. Med. 21: 121-126. [CrossRef] [Medline]
13. Skorupski, K. A., Rodriguez, C. O., Krick, E. L., Clifford, C. A., Ward, R. and Kent, M. S. 2009. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. Vet. Comp. Oncol. 7: 139-144. [CrossRef] [Medline]
14. Vail, D. M., Kravis, L. D., Cooley, A. J., Chun, R. and MacEwen, E. G. 1997. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother. Pharmacol. 39: 410-416. [CrossRef] [Medline]
15. Veterinary Co-operative Oncology Group (VCOG) 2004. Veterinary co-operative oncology group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet. Comp. Oncol. 2: 195-213. [CrossRef] [Medline]